8-K Announcements
5Material company update
Nov 6, 2025·SEC
Material company update
Oct 9, 2025·SEC
Material company update
Sep 29, 2025·SEC
Dogwood Therapeutics, Inc.(DWTX)Earnings, Financials & Key Ratios
DWTX•NASDAQ
Price updated Jun 19, 2026
AboutDogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$0
- EBITDA-$28M-128.9%
- Net Income-$34M-177.4%
- EPS (Diluted)-4.32+65.5%
- ROE-49.23%-35.7%
DWTX Key Insights
Dogwood Therapeutics, Inc. (DWTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 27.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DWTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DWTX Price & Volume
Dogwood Therapeutics, Inc. (DWTX) stock price & volume — 10-year historical chart
Loading chart...
DWTX Growth Metrics
Dogwood Therapeutics, Inc. (DWTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.6%
Return on Capital
10 Years-68.02%
5 Years-67.64%
3 Years-51.66%
Last Year-31.38%
DWTX Recent Earnings
Dogwood Therapeutics, Inc. (DWTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.15+31.8%
$0.22
Rev
—
—
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.26+69.8%
$0.86
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$8.20-566.7%
$1.23
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.99-57.9%
$1.26
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.15vs $0.22+31.8% | — |
| Q2 2026 | Mar 18, 2026 | $0.26vs $0.86+69.8% | — |
| Q4 2025 | Nov 6, 2025 | $8.20vs $1.23-566.7% | — |
| Q3 2025 | Aug 13, 2025 | $1.99vs $1.26-57.9% | — |
Based on last 12 quarters of dataView full earnings history →
DWTX Peer Comparison
Dogwood Therapeutics, Inc. (DWTX) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 | |
 IQV | 28.47B | 167.77 | 21.40 | 5.87% | 8.33% | 22.11% | 2.44 | |
 MEDP | 13.14B | 460.20 | 30.12 | 19.97% | 17.19% | 120.89% | 0.55 | |
 ICLR | 11.18B | 146.00 | 50.34 | -0.37% | 5.98% | 5.2% | 0.39 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 |
Compare DWTX vs Peers
Dogwood Therapeutics, Inc. (DWTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DWTX Income Statement
Dogwood Therapeutics, Inc. (DWTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - | - |
Operating Expenses | 1.96M | 2.18M | 10.01M | 15.64M | 12.32M | 5.45M | 12.23M | 27.97M | 28.61M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.11M | 1.38M | 9.81M | 4.85M | 4.25M | 3.72M | 8.7M | 6.1M | 6.52M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 854.11K | 800.62K | 194.01K | 10.8M | 8.07M | 1.73M | 3.53M | 21.87M | 22.1M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.96M▲ 0% | -2.18M▼ 11.1% | -10.01M▼ 359.3% | -15.64M▼ 56.3% | -12.32M▲ 21.3% | -5.45M▲ 55.8% | -12.23M▼ 124.5% | -27.97M▼ 128.7% | -28.61M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -11.06% | -359.28% | -56.33% | 21.26% | 55.77% | -124.48% | -128.74% | - |
EBITDA | -1.96M | -2.18M | -10.01M | -15.64M | -12.32M | -5.45M | -12.22M | -27.97M | -28.58M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -11.06% | -359.28% | -56.33% | 21.26% | 55.77% | -124.26% | -128.95% | -86.11% |
D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 12.18K | 2.06K | 34.51K |
EBIT | -1.96M | -2.18M | -10.01M | -15.64M | -12.32M | -5.45M | -12.26M | -27.97M | -28.55M |
Net Interest Income | -152.1K | -295.13K | -384.22K | 5.67K | 67.47K | 150.9K | -92.19K | 0 | 269.31K |
Interest Income | 0 | 0 | 0 | 5.67K | 67.47K | 150.9K | 0 | 0 | 269.31K |
Interest Expense | 152.1K | 295.13K | 384.22K | 0 | 0 | 0 | 92.19K | 0 | 0 |
Other Income/Expense | -152.1K | -295.13K | -341K | -319.33K | 67.47K | 150.9K | -122.98K | -6.07M | 327.6K |
Pretax Income | -2.11M▲ 0% | -2.47M▼ 17.0% | -10.35M▼ 318.3% | -15.96M▼ 54.3% | -12.25M▲ 23.3% | -5.3M▲ 56.8% | -12.35M▼ 133.2% | -34.04M▼ 175.6% | -28.29M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -503 | 221.1K | 29.36K |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.65% | -0.1% |
Net Income | -2.11M▲ 0% | -2.47M▼ 17.0% | -10.35M▼ 318.3% | -15.96M▼ 54.3% | -12.25M▲ 23.3% | -5.3M▲ 56.8% | -12.35M▼ 133.2% | -34.26M▼ 177.4% | -28.32M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -17.03% | -318.27% | -54.26% | 23.26% | 56.76% | -133.19% | -177.39% | -28.82% |
Net Income (Continuing) | -2.11M | -2.47M | -10.35M | -15.96M | -12.25M | -5.3M | -12.35M | -34.26M | -28.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -10.93▲ 0% | -12.80▼ 17.1% | -52.50▼ 310.2% | -47.90▲ 8.8% | -27.66▲ 42.3% | -7.05▲ 74.5% | -12.52▼ 77.6% | -4.32▲ 65.5% | -0.84▲ 0% |
EPS Growth % | - | -17.11% | -310.16% | 8.76% | 42.25% | 74.51% | -77.59% | 65.5% | 39.6% |
EPS (Basic) | -10.93 | -12.80 | -52.50 | -47.90 | -27.66 | -7.05 | -12.52 | -4.32 | - |
Diluted Shares Outstanding | 193.3K | 193.3K | 197.08K | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M | 33.54M |
Basic Shares Outstanding | 193.3K | 193.3K | 197.08K | 333.17K | 442.8K | 751.07K | 1.03M | 8.22M | 33.54M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
DWTX Balance Sheet
Dogwood Therapeutics, Inc. (DWTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 42.4K | 315.9K | 31.47M | 15.78M | 8.37M | 4.17M | 16.54M | 8.43M | 15M |
Cash & Short-Term Investments | 30.03K | 309.38K | 29.8M | 14.01M | 7.03M | 3.32M | 14.85M | 6.52M | 13.23M |
Cash Only | 30.03K | 309.38K | 29.8M | 14.01M | 7.03M | 3.32M | 14.85M | 6.52M | 13.23M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 334 | 785 | 324 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 863 | 7.29K | 3.56K | 28.01K | 4.88K | 66.88K |
Total Non-Current Assets | 23.54K | 0 | 0 | 0 | 0 | 0 | 77.76M | 81.74M | 80.2M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 222.65K | 194.93K | 159.29K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 11.81M | 12.4M | 12.19M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 65.71M | 68.99M | 67.83M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 18.13K | 0 | 37.87K |
Other Non-Current Assets | 23.54K | 0 | 0 | 0 | 0 | 0 | 0 | 158.96K | 18.72K |
Total Assets | 65.94K▲ 0% | 315.9K▲ 379.1% | 31.47M▲ 9862.9% | 15.78M▼ 49.9% | 8.37M▼ 46.9% | 4.17M▼ 50.2% | 94.31M▲ 2164.1% | 90.17M▼ 4.4% | 95.21M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 379.11% | 9862.88% | -49.87% | -46.95% | -50.23% | 2164.06% | -4.39% | 6482.2% |
Total Current Liabilities | 1.33M | 1.62M | 1.53M | 1.28M | 1.04M | 358.55K | 3.18M | 3.06M | 2.56M |
Accounts Payable | 145.66K | 35.42K | 368.9K | 353.86K | 573.16K | 111.91K | 1.23M | 760.95K | 144.4K |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 49.7K | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.57K |
Other Current Liabilities | 0 | 0 | 573.48K | 532.68K | 159.7K | 0 | 687.59K | 745.08K | 2M |
Current Ratio | 0.03x | 0.19x | 20.55x | 12.37x | 8.02x | 11.62x | 5.21x | 2.76x | 5.86x |
Quick Ratio | 0.03x | 0.19x | 20.55x | 12.37x | 8.02x | 11.62x | 5.21x | 2.76x | 5.86x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 3.64M | 0 | 0 | 0 | 0 | 26.85M | 12.22M | 12.02M |
Long-Term Debt | 0 | 3.64M | 0 | 0 | 0 | 0 | 15.38M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 154.88K | 105.76K | 446.08K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 11.31M | 12.11M | 48.04M |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.33M | 5.26M | 1.53M | 1.28M | 1.04M | 358.55K | 30.03M | 15.27M | 14.58M |
Total Debt | 0 | 3.64M | 0 | 0 | 0 | 0 | 15.59M | 162.6K | 144.93K |
Net Debt | -30.03K | 3.33M | -29.8M | -14.01M | -7.03M | -3.32M | 737.71K | -6.36M | -13.08M |
Debt / Equity | - | - | - | - | - | - | 0.24x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.46x |
Interest Coverage | -12.90x | -7.38x | -26.04x | - | - | - | -132.96x | - | - |
Total Equity | -1.26M▲ 0% | -4.94M▼ 292.1% | 29.94M▲ 705.8% | 14.5M▼ 51.6% | 7.33M▼ 49.5% | 3.81M▼ 48.0% | 64.28M▲ 1588.5% | 74.9M▲ 16.5% | 80.62M▲ 0% |
Equity Growth % | - | -292.14% | 705.78% | -51.57% | -49.48% | -48.04% | 1588.54% | 16.51% | 11637.02% |
Book Value per Share | -6.52 | -25.57 | 151.92 | 43.52 | 16.55 | 5.07 | 62.54 | 9.11 | 2.40 |
Total Shareholders' Equity | -1.26M | -4.94M | 29.94M | 14.5M | 7.33M | 3.81M | 64.28M | 74.9M | 80.62M |
Common Stock | 12.6M | 12.6M | 830 | 833 | 1.83K | 77 | 133 | 2.97K | 3.34K |
Retained Earnings | -15.15M | -17.62M | -27.97M | -43.93M | -56.17M | -61.47M | -73.82M | -108.08M | -113.06M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -299.13K | -299.13K | -299.13K | -299.13K |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -3.86M | -587.04K | -1.72M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DWTX Cash Flow Statement
Dogwood Therapeutics, Inc. (DWTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.2M | -2.09M | -3.9M | -15.69M | -11.47M | -4.87M | -8.79M | -15.62M | -15.52M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -74.94% | -86.18% | -302.79% | 26.91% | 57.53% | -80.49% | -77.67% | -612.86% |
Net Income | -2.11M | -2.47M | -10.35M | -15.96M | -12.25M | -5.3M | -12.35M | -34.26M | -28.32M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 12.18K | 2.06K | 51.43K |
Stock-Based Compensation | 0 | 0 | 7.43M | 322.88K | 582.66K | 619.97K | 476.02K | 355.64K | 222.89K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | -503 | 221.1K | 31.75K |
Other Non-Cash Items | 48.51K | 65K | -4.26K | 0 | 0 | 0 | 3.65M | 18.19M | 12.49M |
Working Capital Changes | 869.13K | 316.48K | -974.06K | -52.19K | 197.38K | -194.45K | -581.27K | -133K | -2.78K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 65.64K | -89.82K | 51.56K | 270.01K | 219.3K | -461.25K | 219.89K | -532.61K | -990.64K |
Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 3.76M | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 3.76M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 1.15M | 2.37M | 33.38M | -97.6K | 4.49M | 1.16M | 16.7M | 7.28M | 11.2M |
Debt Issued (Net) | 0 | 2.43M | 1.99M | 0 | 0 | 0 | 15.32M | 3M | 3M |
Equity Issued (Net) | 1.22M | 0 | 31.35M | -295.17K | 4.49M | 1.16M | 1.38M | 4.34M | 11.26M |
Dividends Paid | 0 | 0 | -75K | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -295.17K | 0 | 0 | -351 | 0 | 0 |
Other Financing | -69.53K | -58.49K | 112.99K | 197.56K | 0 | 0 | 0 | -53.8K | -3.05M |
Net Change in Cash | -45.49K▲ 0% | 279.36K▲ 714.1% | 29.49M▲ 10454.9% | -15.79M▼ 153.5% | -6.98M▲ 55.8% | -3.71M▲ 46.8% | 11.53M▲ 410.5% | -8.32M▼ 172.2% | -4.31M▲ 0% |
Free Cash Flow | -1.2M▲ 0% | -2.09M▼ 74.9% | -3.9M▼ 86.2% | -15.69M▼ 302.8% | -11.47M▲ 26.9% | -4.87M▲ 57.5% | -8.79M▼ 80.5% | -15.62M▼ 77.7% | -15.52M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -74.94% | -86.18% | -302.79% | 26.91% | 57.53% | -80.49% | -77.67% | -23.83% |
FCF per Share | -6.19 | -10.82 | -19.76 | -47.09 | -25.90 | -6.48 | -8.55 | -1.90 | -0.46 |
FCF Conversion (FCF/Net Income) | 0.57x | 0.85x | 0.38x | 0.98x | 0.94x | 0.92x | 0.71x | 0.46x | 0.55x |
Interest Paid | 0 | 0 | 12.55K | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DWTX Key Ratios
Dogwood Therapeutics, Inc. (DWTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -82.78% | -71.83% | -112.22% | -95.14% | -36.28% | -49.23% | -35.91% |
Return on Invested Capital (ROIC) | - | - | -3675.02% | -2343.15% | -1040.22% | -28% | -31.41% | -31.46% |
Debt / Equity | - | - | - | - | - | 0.24x | 0.00x | 0.00x |
Interest Coverage | -7.38x | -26.04x | - | - | - | -132.96x | - | - |
FCF Conversion | 0.85x | 0.38x | 0.98x | 0.94x | 0.92x | 0.71x | 0.46x | 0.55x |
Related:DWTX Dividend History·DWTX Revenue History·DWTX Price History·DWTX P/E History·DWTX Financial Ratios·DWTX Institutional Holders
DWTX SEC Filings & Documents
Dogwood Therapeutics, Inc. (DWTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
DWTX Frequently Asked Questions
Dogwood Therapeutics, Inc. (DWTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Dogwood Therapeutics, Inc. (DWTX) grew revenue by 0.0% over the past year. Growth has been modest.
Dogwood Therapeutics, Inc. (DWTX) reported a net loss of $28.3M for fiscal year 2025.
Dividend & Returns
Dogwood Therapeutics, Inc. (DWTX) has a return on equity (ROE) of -49.2%. Negative ROE indicates the company is unprofitable.
Dogwood Therapeutics, Inc. (DWTX) had negative free cash flow of $15.5M in fiscal year 2025, likely due to heavy capital investments.